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Abstract: First thought to orchestrate exclusively leukocyte trafficking, chemokines are now
acknowledged for their multiple roles in the regulation of cell proliferation, differentiation, and survival.
Dysregulation of their normal functions contributes to various pathologies, including inflammatory
diseases and cancer. The two chemokine receptor 3 variants CXCR3-A and CXCR3-B, together with
their cognate chemokines (CXCL11, CXCL10, CXCL9, CXCL4, and CXCL4L1), are involved in the
control but also in the development of many tumors. CXCR3-A drives the infiltration of leukocytes to
the tumor bed to modulate tumor progression (paracrine axis). Conversely, tumor-driven changes
in the expression of the CXCR3 variants and their ligands promote cancer progression (autocrine
axis). This review summarizes the anti- and pro-tumoral activities of the CXCR3 variants and their
associated chemokines with a focus on the understanding of their distinct biological roles in the
tumor microenvironment.
Keywords: chemokine receptor; CXCR3; CXCL11; CXCL10; CXCL9; CXCL4; tumor microenvironment;
GPCR; ACKR3/CXCR7
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1. Introduction
Chemokines, or chemotactic cytokines, are small, secretory proteins that form the largest group
within the cytokine family [1]. They bind to their cognate chemokine receptors, which belong
to the G protein-coupled receptor (GPCR) superfamily, and mediate cellular responses as a result
of downstream signaling pathways initiated by the activation of G proteins and regulated by the
recruitment of arrestins [1–3]. To date, 48 chemokines and 23 receptors have been identified in humans.
The chemokine–receptor network is highly intricate; a chemokine can bind one or many receptors, while
a receptor usually recognizes several chemokines [1,4]. Moreover, a recent paradigm shift brought to
light the concept known as biased signaling according to which GPCRs, including chemokine receptors,
depending on the ligand or cellular context, trigger distinct signaling pathways [3,5,6]. Chemokines
primarily arbitrate various immune responses through the migration of chemokine-receptor-expressing
leukocytes to the target tissues, while they also orchestrate the development and maintenance of
lymphoid or non-lymphoid tissues by inducing the migration, proliferation, and differentiation of
stromal and immune cells [7–12]. In addition, chemokines play key roles in the tumor microenvironment
(TME) as they are secreted by and act on the different cellular components comprising tumor cells, T- and
B-lymphocytes, natural killer (NK) cells, macrophages, dendritic cells (DCs), fibroblasts, and vascular
and lymphatic endothelial cells and their associated pericytes. Together with other soluble factors such
as growth factors, inflammatory cytokines, and extracellular matrix enzymes, they contribute to cancer
development and the formation of a cancer-specific immunity, influencing the maturation, activation,
and trafficking of tumor-infiltrating immune cells [11,13–19].
The interferon (IFN)-gamma inducible chemokines CXCL11, CXCL10, and CXCL9, and the
platelet-derived chemokines CXCL4 and its non-allelic variant CXCL4L1, exert their biological function
by binding to the IFN-gamma inducible chemokine receptor CXCR3 [6,20–22]. Interestingly, due to
alternative splicing of the CXCR3 mRNA, three variants have been reported, CXCR3-A, CXCR3-B,
and CXCR3-Alt, which exhibit differences in their expression profiles, their N or C terminus, and the
number of transmembrane domains (Figure 1). These structural differences alter the physiological
characteristics of the receptors, including ligand-binding properties, signaling pathways, and cellular
responses [23]. CXCR3-A and CXCR3-B are the two variants that have been best studied. They
differ by a 52-amino acid (AA) extension at the N terminus of CXCR3-B and exert opposing cellular
effects [24]. On the one hand, binding of CXCL11, CXCL10, and CXCL9 to the CXCR3-A variant induces
chemotaxis and proliferation of cells by activating Gi and Gq proteins and triggering their downstream
signaling pathways, including the intracellular Ca2+ release, ERK1/2, and Akt pathways [5,23,25–34].
The activation of CXCR3-A by CXCL4 and its variant CXCL4L1 remains to be elucidated [30,31,35]. On
the other hand, stimulation of CXCR3-B by these chemokines inhibits cell migration and proliferation
and induces apoptosis. The mechanism behind this opposite cellular response driven by CXCR3-B is
still unclear; however, one study suggests a coupling to the Gs protein [24].
While CXCR3 and its endogenous ligands are mainly involved in inflammation and wound
healing [8,36], they have also been described to have a dual role in tumor progression and immunity.
This review aims to outline the impact of the CXCR3 ligand–receptor axis and its expression changes
on the TME with a focus on the CXCR3-A and CXCR3-B variants.
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Figure 1. Schematic representation of CXCR3 variants. Due to alternative splicing of the pre-mRNA of
the CXCR3 gene, located in chromosome X, three CXCR3 variants can be generated. The CXCR3-A
variant is the product of the splicing of the exon 1 and exon 3 within the CXCR3 gene. The assembly of
exon 2 and exon 3 results in the CXCR3-B variant, which has an N terminus longer by 52 amino acids
(AAs) compared with CXCR3-A. The removal of the intron, exon 2, and a 337-bp region within the third
exon during RNA splicing results in the CXCR3-Alt variant that comprises the N terminus and the first
four transmembrane domains identical to CXCR3-A, as well as a possible fifth transmembrane region
and a C terminus which are different from CXCR3-A and -B. The primers used to detect CXCR3-A, which
also recognize CXCR3-B, and CXCR3-B are represented by the black and purple arrows, respectively.
2. The Crosstalk of the CXCR3 Variants and Their Chemokine Ligands Within the Tumor
Microenvironment
Chemokines are abundantly present in the TME and play key roles in inducing proliferation of
benign and malignant cells, leukocyte migration, and angiogenesis [11,12,37,38]. These processes can
be initiated and maintained in paracrine and autocrine fashions.
2.1. CXCR3-A on Leukocytes Mediates their Migration to the TME to Modulate Tumor Progression
The presence of tumor-infiltrating leukocytes (TIL) in the TME is known to influence tumor
development [39]. Following the discovery of CXCR3-A on activated T-lymphocytes [25] and the
anti-tumoral activity of CXCL10 [40], the possibility of an anti-tumoral response through the migration
of CXCR3-A+ leukocytes to the TME was proposed [41]. The importance of CXCR3-dependent
anti-tumoral activity was confirmed by Hensbergen et al. where CXCL11-producing EL4 lymphoma
cells, injected in mice, were rejected due to the infiltration of CXCR3+ CD8+ T lymphocytes and
macrophages [42]. Similar observations were reported in murine models of renal cell carcinoma (RCC)
(RENCA) and spontaneous melanoma (B16F10) where the reduced tumor growth resulted from an
increased presence of CXCR3-A-expressing CD4+ and CD8+ lymphocytes and NK cells in the tumor
bed [43–45]. In another study, melanoma (B16F10) or breast cancer (E0771) cells injected in CXCR3−/−
mice showed a significant increase in tumor growth compared to wild type (WT) mice, which was
associated with a lower prevalence of CD8+ and CD4+ T cells as well as NK cells. This TIL-dependent
anti-tumoral activity was furthermore validated in B16F10 tumor-bearing Rag2−/− mice, which showed
a significantly increased tumor growth when transferred with CXCR3−/− cytotoxic T-lymphocytes
(CTLs) compared to WT CTLs [46]. Such anti-tumoral activity of CXCR3-A+ leukocytes was also
detected in human breast and gastric cancers as well as in RMA lymphoma [47–49]. Interestingly, the
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regressive characteristic of melanoma or certain melanocytic lesions was proposed to depend on the
increased attraction of CXCR3-A+ cytotoxic lymphocytes to the TME [50].
In contrast, the higher prevalence of CXCR3+ regulatory T cells (Tregs) in human ovarian
carcinomas was suggested to dampen the effector cell response, thus favoring the progression of the
tumor [51]. This pro-tumoral effect of CXCR3+ Tregs was also observed in hepatocellular carcinoma
(HCC), where a correlation could be made between CXCR3–CXCL10-dependent Treg infiltration and
increased tumor growth and HCC recurrence after liver transplantation [52]. Moreover, in a chemically
inducible murine model of skin carcinoma, CXCR3 knockout (KO) mice developed fewer tumors
compared to WT mice. This observation was linked to a reduced presence of CXCR3-expressing CD3+
T cells, suggesting a cell proliferative effect on epidermal cells and an pro-tumoral activity of these
TIL [53].
Taken together, these data suggest that the expression of CXCR3-A on leukocytes is needed to
attract them to the TME and allows an anti-tumoral activity that diminishes tumor growth. However,
the attraction of Tregs or other T-lymphocytes to the TME could also have a pro-tumoral effect by
inducing cell proliferation and inhibiting the antitumor activity of effector leukocytes.
Of note, an adequate recruitment of CTLs in the tumor bed is not always observed. Correlated to
a poor survival, it was for instance demonstrated that only 16% of patients with esophageal squamous
cell carcinomas (ESCCs) or adenocarcinomas showed detectable CD8+ T cell infiltration within the
tumor [54]. In fact, insufficient recruitment of activated T lymphocytes to the tumor bed is also
recognized as one of the major hurdles in the current immunotherapeutic approaches [55]. Notably, the
relevance of CXCR3-driven responses in immunotherapy has been demonstrated in several studies. In a
B16-OVA mouse model, Mikucki et al. identified CXCR3-mediated trafficking at the tumor vasculature
as important for effective T-cell-based cancer therapy by showing that CXCR3 is required for the
extravasation of CTL to the tumor bed [45]. Similarly, in a B16 melanoma mouse model, the deletion
of CXCR3 in CTLs lead to an impaired anti-tumoral response due to the failure of CTL infiltration
in the TME upon anti-PD-1 treatment, suggesting CXCR3-dependent anti-PD-1 based anti-tumoral
response [46]. Moreover, the blockade of PD-1 on naïve T cells enhanced CXCR3 expression and their
absolute number in the spleen [56]. These studies show that CXCR3 is a potential target to increase the
effectiveness of current immunotherapies.
2.2. CXCR3-A on Malignant Cells in the TME Contributes to Tumor Growth and Dissemination
As described above, the expression of CXCR3-A on leukocytes mediates their migration to the
TME to exert their anti- and pro-tumoral activity; however, the CXCR3-A variant is also known
to induce proliferation of various cell types, including human mesangial cells [24]. Therefore, the
presence of CXCR3-A on tumor cells can induce an adverse effect by promoting and sustaining tumor
development. Indeed, an increased proliferation of malignant glioma cells compared with normal
astrocytes [57] and an anti-apoptotic effect in CXCR3-A-overexpressing human myeloma cell lines
(HMCLs) was observed after CXCL10 treatment [58]. The increased expression of CXCR3-A on stage II
colorectal cancer (CRC) and papillary thyroid cancer (PTC) cells was also associated with increased
tumor development and negative prognosis [59,60]. In line with this, immunohistochemical analysis
of localized clear cell RCC patient samples showed strong staining for CXCR3, which was correlated
with a negative disease prognosis [61].
In addition to tumor development, expression of CXCR3-A on tumor cells promotes their
dissemination. B16F10 melanoma injected into the footpads of mice showed macroscopic metastatic
tumors in the lymph nodes already after one week, which could be attenuated with antisense CXCR3-A
RNA [62]. An immunohistological analysis of primary invasive cutaneous melanoma samples from
patients also supported the implication of CXCR3-A in tissue invasion and metastasis of malignant
cells [63]. Furthermore, a metastatic potential conferred by CXCR3-A was observed in other human
diseases, including epidermotropic and other B-cell disorders [64,65], glioblastoma (GBM) [66,67],
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CRC [68,69], high-grade serous ovarian cancer (HGSC) [70], lung adenocarcinoma [71] and breast
cancer [72,73].
In conclusion, the expression of CXCR3-A on malignant cells leads to an increased proliferation
and dissemination.
2.3. CXCR3-B Has an Anti-Proliferative Effect in the Tumor Microenvironment
In contrast to CXCR3-A, the CXCR3-B variant was shown to inhibit cell migration and
proliferation [24]. CXCR3-B was first detected on human microvascular endothelial cells
(HuMVECs) [24], but has also been found on CD4+ T lymphocytes [74], airway epithelial cells [75],
and pericytes [76]. Although CXCR3-B is often expressed concomitantly with CXCR3-A, distinct
CXCR3 variant expression levels can be observed on diverse cell types. Endothelial cells and pericytes
abundantly express CXCR3-B [24,76], whereas CXCR3-A is not detectable [76,77], and activated T
lymphocytes show higher CXCR3-A expression levels compared with CXCR3-B [31]. Various cancers
evolve mechanisms to shift the CXCR3 variant expression levels towards ratios that are more beneficial
for tumor maintenance or progression. For instance, human RCC downregulate CXCR3-B, which
results in the upregulation of the anti-apoptotic heme oxygenase-1 (HO-1) and an increased tumor
cell proliferation and dissemination [78,79]. Similarly, lower CXCR3-B mRNA levels were observed
in ovarian and breast cancer cells compared with non-cancerous epithelial cells [80,81]. Moreover,
decreasing the expression of CXCR3-B in breast cancer cells in vitro, using CXCR3-B-specific siRNA,
resulted in increased cell proliferation and expression of anti-apoptotic proteins [81,82]. In addition
to the inhibitory effect of CXCR3-B on cell proliferation, it has been observed that a rise in CXCR3-B
expression could lead to increased tumor necrosis and lower the metastatic ability of tumor cells [83,84].
Of note, cancer stem cell-like properties upon CXCR3-B overexpression were reported in vitro in a
breast cancer cell line, which could be prevented by silencing its mRNA [84].
Overall, it seems that cancer cells lower their expression of CXCR3-B to promote tumor
proliferation, survival and dissemination and that this cellular effect can be reversed by enhancing
CXCR3-B expression.
2.4. Is the CXCR3-B Variant Involved in Angiogenesis Regulation?
Tumors require adequate blood supply to obtain the sufficient oxygen, nutrients and other
metabolic components to ensure their growth and survival. In contrast to normal angiogenesis, in
which new blood vessels mature rapidly and show slow cell turn-over, tumor angiogenesis is an
uncontrolled process where new blood vessels are formed in an irregular fashion [85,86]. Due to the
high expression of CXCR3-B on endothelial cells and the angiostatic effect of CXCL10, CXCL9, and
CXCL4 [24,87–90], it was proposed that the CXCR3-B variant could be responsible for this negative
impact on tumor angiogenesis. Arenberg et al. indeed reported a decrease in angiogenesis and
neovascularization in squamous cell carcinoma (SCC) after addition of CXCL10 in the TME that
resulted in an attenuation in tumor growth and dissemination to the lung [91]. A similar observation
was made following injection of CXCL9 to the tumor site in a mouse RENCA model [43]. In contrast,
a rise in CXCL11 had no impact on the angiogenesis of mouse EL4 lymphoma cells nor human
CRC [42,92]. Considering the expression of CXCR3 variants was not analyzed in these studies, one can
only speculate that the inhibitory effect of these chemokines on tumor angiogenesis is driven through
CXCR3-B present on endothelial cells, a phenomenon which may be cancer-type-dependent.
Although the above-mentioned data point to CXCR3-B-dependent angiostatic and inhibitory
effects on cell proliferation, it has also been suggested that these are instead GAG-mediated. Indeed,
both WT and CXCR3 KO endothelial cells showed an equivalent inhibitory effect on cell proliferation
in the presence of CXCL10, which could not be reversed by neutralizing anti-CXCR3 antibodies.
Moreover, the generation of a CXCL10 mutant devoid of CXCR3 signaling properties could also inhibit
human umbilical cord endothelial cell (HUVEC) proliferation [93].
Cells 2019, 8, 613 6 of 17
2.5. The CXCR3 Ligands are Upregulated in the TME and Act in an Autocrine and Paracrine Manner
Tumor cells as well as endothelial and immune cells secrete chemokines in the TME, which induce
the recruitment of immune cells, modulate tumor immunity and promote tumor cell proliferation
as well as metastasis [12]. Cancer cells also control the production and the activity of chemokines
through the transcriptional silencing [94–96] or the post-translational modifications, via dipeptidyl
peptidase 4 (DPP4 or CD26) [97,98]. These modifications undermine the attraction of tumor-invading
lymphocytes, which impairs their anti-tumor effect [99,100] and the success of immunotherapy. In
addition, CXCR3-endogenous ligands have been described to activate distinct signaling pathways,
leading to specific cellular responses. For example, CXCL9 and CXCL10 induce effector Th1/Th17 cells
and CXCL11 drives a Treg and Th2-biased effector cell polarization upon activation of CXCR3 on CD4+
T cells, while they upregulate tumor cell-related proteins that are beneficial for their survival, such as
PD-L1 [21,101,102]. Here, we give an outline on the impact of the TME on the expression and secretion
of CXCL11, CXCL10, CXCL9, CXCL4 and its variant CXCL4L1, and the effect of these chemokines on
the different cellular components present within the TME.
2.5.1. CXCL11
Although CXCL11 is the most potent CXCR3 ligand [103], its role in CXCR3-driven processes is
sometimes overlooked due to its impaired production in certain mouse strains; such as in C57BL/6 mice
where a 2-bp insertion after the start codon results in a premature stop codon and ultimately CXCL11
null mutant mice [101,104,105]. CXCL11 is also less available compared with CXCL9 and CXCL10,
whether in health or disease state [106–108]. For CXCL11, being the full agonist of CXCR3 [109],
its production may also be submitted to stricter regulation. In addition, ACKR3, formerly known
as CXCR7, is a scavenger receptor for CXCL11 that may reduce the availability of CXCL11 in vivo
and in the tumor bed. Indeed, ACKR3 has been shown to be upregulated on various tumor cells as
well as on tumor-associated vasculature, therefore potentially interfering with the CXCR3–CXCL11
interactions [103,110–112].
Nevertheless, several studies pinpointed the importance of CXCL11–CXCR3 axis within the TME.
It has been reported that mice challenged with EL4 T-cell lymphoma cells genetically modified to
produce murine CXCL11 attracted more CD8+ lymphocytes and macrophages with anti-tumoral
activity to the TME compared to WT EL4 T-cell lymphoma cells [42]. On the other hand, a study on
human colon adenocarcinoma showed enhanced tumor growth and invasiveness after injection of
CXCL11 to the TME [92]. It has also been described that the repression of CXCL11 in CRC tissues
diminished the tumor cell growth and metastasis [113]. In addition, the observed increased expression
of CXCL11 in HCC cells was linked with the upregulation of stem cell-related genes and the acquisition
and maintenance of self-renewal and tumorigenic properties of tumor-initiating cells through an
autocrine axis [114].
2.5.2. CXCL10
Although CXCL10 is only a partial agonist of CXCR3, its impact on many human pathologies
including cancer has been extensively studied. In glioma cells, for example, the expression of
CXCL10 is significantly upregulated when compared with healthy astrocytes and has been shown to
increase cell proliferation by acting on CXCR3 in an autocrine manner [57]. This pro-tumoral CXCL10
feed-forward loop was also observed in breast cancer; albeit, CXCL10 also attracted more CD4+ and
CD8+ lymphocytes to the TME, in a paracrine manner, which attenuated tumor progression [115].
This pro- and anti-tumoral activity of CXCL10 could also be observed in CRC. Stage IV CRC
patients showed an increased presence of CXCL10 in the TME, which was associated with a poor
prognosis and promoted metastasis to the liver [116,117]. In contrast, higher secretion of CXCL10
in CRC increased the infiltration of CD8+ T lymphocytes and inhibited the ability of cancer cells
to metastasize [118]. In addition, patients with ESCC showing higher CXCL10 expression had a
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better overall survival rate when compared with CXCL10-negative patients [119], while enhanced
proliferation and metastatic behavior of melanoma tumor cells could be linked to higher CXCL10
secretion [120].
CXCL10 having opposing effects on TME that may occur simultaneously, the overall outcome of
the disease seems to be tumor-type dependent and thus hard to predict.
2.5.3. CXCL9
Similar to CXCL10, CXCL9 is one of the most extensively studied CXCR3 chemokines in cancer
and also plays a dual role in the TME. CXCL9 gene upregulation in CRC and non-small-cell-lung-cancer
(NSCLC) patient samples correlated with an increased overall survival, suggesting a beneficial impact of
higher secretion of this chemokine in the TME [121,122]. In line with this observation, higher secretion
of CXCL9 in HGSC and fibrosarcoma tumors also resulted in an increased overall survival presumable
due to an enhanced attraction of leukocytes, in particular T and NK cells, to the tumor bed [95,123].
The anti-tumoral activity of CXCL9 could also be observed in lymphocyte-rich gastric carcinoma (GC)
and regressing Burkitt’s lymphoma tumors. These regressing tumors showed a higher prevalence of
CXCL9 in the TME compared with conventional tumors and exhibited an increased presence of TIL
and tumor necrosis rate [124,125]. In contrast, it has been reported that the higher CXCL9 levels in
melanoma—secreted by the melanoma endothelial cells—disrupt the endothelial barrier, which in turn
leads to a higher dissemination of melanoma cells. This transendothelial migration of the tumor cells
was diminished upon addition of anti-CXCL9 monoclonal antibody (mAb) [126]. The CXCL9-mediated
metastasis was also observed in tongue squamous cell carcinoma (TSCC). TSCC cell show an increased
CXCL9 and CXCR3 expression, which results in cytoskeleton alterations and decreased cell adhesion
molecules that promotes tumor cell invasion and migration to the lymph nodes [127]. Interestingly, in
follicular lymphoma (FL), elevated levels of CXCL9 result in lower event-free survival after treatment
with immunotherapy implying a potential negative role of this chemokine after cancer treatment [128].
Thus, depending on the tumor cell type, CXCL9 can have either an adverse or a beneficial effect. This
beneficial effect appears to rely on leukocyte attraction to the TME in a paracrine fashion; however, the
adverse effect of CXCL9 on the malignant cell might not be direct as for CXCL10.
2.5.4. CXCL4 and its CXCL4L1 Variant
While CXCL4 is mainly released after activation of platelets, it can also be secreted by stromal cells
and tumor cells. In the two most frequent types of human lung adenocarcinomas (KRAS and TP53)
and in CRC, an increase in CXCL4 expression was detected and correlated to lower patient survival
probably due to its proliferative effect on tumor cells and anti-proliferative effect on CTLs [129–131]. The
CXCL4L1 non-allelic variant has also been described to bind to CXCR3-A and -B [132]. The production
of CXCL4L1 in melanoma, lung carcinoma and pancreatic adenocarcinoma (PDAC) inhibits tumor
growth as well as neovascularization. Furthermore, CXCL4L1, as well as CXCL4, are able to recruit T
cells, NK cells and DC to the TME, which may contribute to their anti-tumoral activity [132–135].
3. Technical Hurdles to Studying the CXCR3 Variants
The identification of the CXCR3-B variant, with its opposite cellular responses, raised new issues
pertaining to the study and validation of the exact expression profile, signaling and the differential
contribution of the two isoforms in CXCR3-mediated processes. Variant-specific tools were thus needed
to be able to attribute the various cellular responses on the different cell types to CXCR3-A or CXCR3-B.
Nucleotide probes, or primers, were the first easily accessible tools to detect and distinguish
endogenous expression of CXCR3-A- and CXCR3-B-specific transcripts in tissue and cells. The most
frequently used primers, described by Lasagni et al., detect the spliced mRNA encoding both CXCR3-A
and CXCR3-B as they bind to sequences that are common to the two variants. Nevertheless, the
PCR products can be distinguished based on their different DNA band size. Primers designed for
specific detection of CXCR3-A or CXCR3-B were also reported [24] (Figure 1). The CXCR3-A-specific
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primer aligns with the nucleotide sequence coding for the first seven amino acids present only in this
variant [136] while the primer specific to CXCR3-B aligns within its extended N terminus. Besides
PCR-based approaches, another application of nucleotide probes is in situ hybridization. This technique
was used to screen for mRNA expression of the CXCR3 variants directly in slices of fixed tissues
allowing the direct visualization of the receptor distribution and identification of receptor-positive cell
types [137].
Variant-specific nucleotide probes proved to be easily manufactured and useful tools to evaluate
the gene expression levels. However, confirming the presence of CXCR3 at protein level and, in
particular, on the cell surface turned out to be a more difficult task. For the time being, the anti-CXCR3-A
antibodies also recognize the CXCR3-B variant due to the usage of CXCR3-A N-terminus-derived
peptides for immunization. The production of the first CXCR3-B-specific mAb raised against the
extended 52-AA N terminus and its use in immunofluorescence and immunohistochemistry was first
described by Lasagni et al. [24]. Meanwhile, other CXCR3-B-specific mAbs, using different CXCR3-B
N-terminus-derived peptides as immunogen, are available but usually show an application spectrum
limited to ELISA or Western Blot. To circumvent the staining of both CXCR3 isoforms, an alternative
may be the use of conformational antibodies against each variant as previously generated for other
GPCRs or chemokine receptors, including CXCR4 [138] CCR5 [139] and ACKR3 [109]. Indeed, the
opposite cellular response of the two CXCR3 variants suggests that the presence of the N-terminal
extension of CXCR3-B modifies the general tertiary structure of the receptor and might therefore expose
different discontinued epitopes compared with CXCR3-A. Although their use would be limited to the
detection of CXCR3 in its native conformation, it would help to confirm and quantify the presence of
the two variants on the cell surface and understand the biology behind the selective receptor expression
on the various cell types of the TME.
The diverse cellular effects of the CXCR3 variants were proposed to rely on the activation of
different downstream signaling pathways. To investigate and identify CXCR3 variant-specific pathways,
novel variant-selective modulators (antagonists, agonists or allosteric modulators) are needed as the
currently used endogenous chemokines bind and activate both variants almost indifferently. Although
CXCR3-A small-molecule modulators have been generated, their activity on CXCR3-B remains to be
elucidated [106,140–142]. In addition, no CXCR3-B-specific small molecules have been reported so
far. Therefore, the generation of small modulators is timely and would enable to unravel the CXCR3
variants signaling and could hold potential therapeutic value.
4. Conclusions, Challenges, and Future Directions
Over the last two decades, much effort has been made to understand the biology of the chemokine
receptor CXCR3. Although the mechanism controlling the alternative splicing of both CXCR3 variants
remains to be elucidated, numerous data on their signaling pathways and their respective contribution
in tumor development and immunity have been generated.
On the one hand, it was shown that tumor cells can manipulate the expression of the CXCR3
variants in a way that is overall more beneficial for their maintenance. Indeed, by upregulating the
expression of CXCR3-A and lowering the expression of CXCR3-B at their surface, tumor-initiating cells
are able to enhance their proliferative potential and survival through autocrine stimulation loops that
are further reinforced by the simultaneous upregulation of the expression of the CXCR3 ligands in
the TME.
On the other hand, the increased secretion of CXCR3 ligands within the TME was shown to
enhance the recruitment and the infiltration of various leukocytes into the tumor bed in a paracrine
fashion, thereby modulating tumor progression. In a similar manner, chemokines participate in the
control of metastasis of CXCR3-expressing tumor cells (summarized in Figure 2).
Cells 2019, 8, 613 9 of 17
Figure 2. Illustration of the roles of CXCR3 variants and their ligands in the tumor microenvironment.
The increased secretion of CXCR3 ligands in the TME, originating from the tumor cells, results in an
increased chemokine gradient (1) and the recruitment of CXCR3-A+ leukocytes towards the tumor
(paracrine axis) (2). The Th1-related immune cells drive anti-tumoral responses, while the recruited
CXCR3-A+ Tregs have a pro-tumoral effect by suppressing other immune cells. The secreted chemokines
also bind to CXCR3-A or CXCR3-B, present on secreting (autocrine axis) and neighboring tumor cells,
and depending on the cellular context, may induce a proliferative or inhibitory effect (3). Moreover,
the chemokines in close proximity to the endothelial cells attenuate the angiogenesis by activating
CXCR3-B (4). In addition, the increased expression of CXCR3-A, together with decreased CXCR3-B
expression, on the tumor cells enable them to detach from the tumor mass and disseminate to a distant
tissue (5).
The demonstration of the impact of the CXCR3 axis in cancer points to its potential interest as a
therapeutic target. However, the dual activity of CXCR3-A in the proliferative loops and the attraction
of immune cells to the tumor bed, and the opposing roles of the CXCR3 variants’ ligand–receptor
axis, as well as ligand and cell context bias, are important aspects that need to be considered for the
development and use of anti-CXCR3 drugs or neutralizing antibodies. In addition, other players in the
TME, including growth factors, inflammatory cytokines, and extracellular matrix enzymes, and the
impact of the tumor on the microenvironment, such as induction of hypoxia, influence the CXCR3
axis and add yet another level of complexity to CXCR3-regulated processes, ultimately making the
outcome of potential blockade hard to predict.
Therefore, a better understanding of all aspects of the biology of CXCR3 variants, including
their exact signaling pathways and cellular responses in the tumor-microenvironment context, is
urgently needed before envisaging the CXCR3 variants as potential anti-tumoral targets and the
development of CXCR3 variant-specific drugs to be used for combined therapy, for example with
anti-PD-1 immunotherapy, to turn cold to hot tumors.
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